贞芪扶正胶囊和贞芪扶正汤剂在辅助治疗晚期非小细胞肺癌化疗患者中的应用效果  

Application Effect of Zhenqi Fuzheng Capsule and Zhenqi Fuzheng Decoction in Patients with Advanced NSCLC Undergoing Adjuvant Chemotherapy

作　　者：杜晓娜 王永伏 张萌 DU Xiaona;WANG Yongfu;ZHANG Meng(Department of Pharmacy,Hengshui Hospital of Traditional Chinese Medicine,Hengshui,Hebei 053000,China)

机构地区：[1]衡水市中医医院药剂科,河北衡水053000

出　　处：《临床误诊误治》2024年第7期91-96,共6页Clinical Misdiagnosis & Mistherapy

基　　金：河北省中医药管理局科研计划项目(2024504)。

摘　　要：目的探讨贞芪扶正胶囊和贞芪扶正汤剂在辅助治疗晚期非小细胞肺癌(NSCLC)化疗患者中应用效果。方法将2021年1月—2023年2月收治接受化疗的晚期NSCLC 100例,随机分为胶囊组、汤剂组各50例。胶囊组给予贞芪扶正胶囊,汤剂组给予贞芪扶正汤剂。比较2组临床疗效、化疗毒副反应及治疗前后肿瘤标志物[胃泌素释放肽前体(Pro-GRP)、血清鳞状细胞癌抗原(SCC)、细胞角蛋白片段19(CYFRA21-1)、癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)]、细胞免疫功能(CD3+、CD4+、CD8+、CD4+/CD8+)、体液免疫功能(IgA、IgM、IgG)、生存情况[Karnofsky行为状态评分(KPS)]、癌因性疲乏程度量表(PFS-R)评分。结果2组均无脱落病例。胶囊组客观缓解率、疾病控制率[22.00%(11/50)、92.00%(46/50)]与汤剂组[26.00%(13/50)、94.00%(47/50)]比较差异无统计学意义(P>0.05)。2组治疗后SCC、Pro-GRP、CEA、CYFRA21-1、NSE均低于治疗前(P<0.05);2组CD3+、CD4+、CD8+、CD4+/CD8+及IgA、IgM、IgG水平组间、组内比较差异无统计学意义(P>0.05)。2组治疗后KPS评分均高于治疗前,PFS-R评分均低于治疗前(P<0.05)。2组毒副反应发生率比较差异无统计学意义(P>0.05)。结论贞芪扶正汤和贞芪扶正胶囊应用于晚期NSCLC化疗辅助治疗效果相似,均能改善患者免疫功能,减轻患者癌因性疲乏,抑制肿瘤标志物表达,二者具有等效性。Objective To investigate the application effect of Zhenqi Fuzheng capsule and Zhenqi Fuzheng decoction in advanced NSCLC patients undergoing adjuvant chemotherapy.Methods A total of 100 patients with advanced NSCLC undergoing chemotherapy from January 2021 to February 2023 were randomly divided into capsule group(n=50)and decoction group(n=50).The capsule group was given Zhenqi Fuzheng capsule,and the decoction group was given Zhenqi Fuzheng decoction.The clinical efficacy,toxic and side effects of chemotherapy and tumor markers[pro-gastrin releasing peptide(Pro-GRP),serum squamous cell carcinoma antigen(SCC-Ag),cytokeratin 19 fragment antigen 21-1(CYFRA21-1),carcinoembryonic antigen(CEA),neuron-specific enolase(NSE)],cellular immune function(CD3+,CD4+,CD8+,CD4+/CD8+),humoral immune function(IgA,IgM,IgG),survival status[Karnofsky performance status(KPS)],and cancer-related fatigue[Revised Piper Fatigue Scale(PFS-R)score]before and after treatment were compared between the two groups.Results There were no shedding cases in both groups.There was no significant difference in objective remission rate and disease control rate between capsule group[22.00%(11/50),92.00%(46/50)]and decoction group[26.00%(13/50),94.00%(47/50)](P>0.05).After treatment,SCC,Pro-GRP,CEA,CYFRA21-1 and NSE in the two groups were lower than those before treatment(P<0.05).There was no significant difference in the levels of CD3+,CD4+,CD8+,CD4+/CD8+and the levels of IgA,IgM and IgG between the two groups(P>0.05).KPS score after treatment was higher than that before treatment,while PFS-R score was lower than that before treatment(P<0.05).There was no significant difference in the incidence of toxic and side effects between the two groups(P>0.05).Conclusion Zhenqi Fuzheng decoction and Zhenqi Fuzheng capsule have similar effects in adjuvant chemotherapy for advanced NSCLC patients.Both have equivalent effects in improving patients'immune function,reducing patients'cancer-related fatigue,and inhibiting the expression of tumor markers.

关 键 词：肺肿瘤 贞芪扶正胶囊 贞芪扶正汤剂 胃泌素释放肽前体 细胞角蛋白片段19 癌胚抗原 免疫功能 癌症疲乏程度 

分 类 号：R734.2[医药卫生—肿瘤]